SkinBioTherapeutics (LSE:SBTX) expects revenue to increase approximately 20.5% to £4.7 million for the financial year ended 30 June 2026, according to a pre-close trading update.
The AIM-listed skin health and life sciences company anticipates an adjusted EBITDA loss of £1.6 million, while its cash balance declined to £1.5 million following exceptional costs associated with an investigation conducted earlier in the year.
The company also confirmed the permanent appointments of Rachel Parsonage as chief executive officer and Alyson Levett as chair, following their periods in interim positions.
Management said early trading in FY2027 was ahead of internal expectations, with the board prioritising revenue growth, operating performance and cash management.
Revenue Expected to Increase 20.5% to £4.7 Million
SkinBioTherapeutics expects to report revenue of approximately £4.7 million for FY2026, representing growth of 20.5% compared with the previous financial year.
The increase was primarily driven by a full-year contribution from Bio-Tech Solutions, alongside modest growth in other parts of the business.
The group operates across skin health, consumer wellness, contract manufacturing and distribution.
Its portfolio includes Dermatonics, Bio-Tech Solutions and AxisBiotix, alongside its proprietary SkinBiotix technology.
The revenue figures remain preliminary ahead of the publication of the company’s full-year results.
Adjusted EBITDA Loss Expected at £1.6 Million
SkinBioTherapeutics anticipates an adjusted EBITDA loss of £1.6 million for the financial year.
The company also reported a reduction in its cash balance to £1.5 million.
Exceptional costs associated with the investigation conducted earlier in the year amounted to £1.2 million and contributed to the reduction in cash.
Management stated that the company’s remaining cash reserves were sufficient, although the supplied announcement does not specify a cash runway or provide further details of future funding requirements.
The board has identified cost control and cash management as priorities for FY2027.
Rachel Parsonage Confirmed as Chief Executive
SkinBioTherapeutics confirmed that Rachel Parsonage has been appointed permanent chief executive officer after serving in the role on an interim basis.
Alyson Levett has also been appointed permanent chair, having previously held the position on an interim basis.
The appointments follow a forensic investigation earlier in the year.
The company has not provided details of the investigation’s findings in the supplied update.
Levett will retain temporary responsibility for the Audit & Risk Committee while the company continues to develop its board structure.
Board Recruitment and Finance Leadership Update
SkinBioTherapeutics is continuing discussions regarding the appointment of an additional non-executive director.
The company described these discussions as being at an advanced stage, although no appointment has been confirmed.
Anita Breslin is also serving as interim chief financial officer.
The board changes form part of the company’s ongoing governance arrangements following the earlier investigation.
The company has not announced a timetable for completing the additional non-executive director appointment or making a permanent chief financial officer appointment.
Early FY2027 Trading Ahead of Internal Expectations
SkinBioTherapeutics reported that trading during the early part of FY2027 was ahead of management’s internal expectations.
The company has not disclosed specific revenue figures or quantified the extent to which trading exceeded its forecasts.
The board has identified three principal operating priorities for the new financial year: increasing revenue, improving underlying operating performance and controlling costs and cash expenditure.
These priorities follow a financial year in which revenue increased but the company continued to report an adjusted EBITDA loss.
Management intends to focus on the performance of its existing businesses while maintaining financial controls.
Skin Health and Manufacturing Operations
SkinBioTherapeutics develops products and technologies focused on skin health, including topical creams and oral supplements.
Its proprietary SkinBiotix technology originated from research at the University of Manchester.
The group also operates contract manufacturing and distribution activities for skin and healthcare products.
Its portfolio includes consumer brands and manufacturing businesses serving the beauty, wellness and dermatology markets.
Bio-Tech Solutions was the principal contributor to the group’s expected revenue growth in FY2026, reflecting its first full-year contribution.
Outlook
SkinBioTherapeutics expects to report FY2026 revenue of approximately £4.7 million and an adjusted EBITDA loss of £1.6 million when it publishes its full-year results.
The company enters FY2027 with £1.5 million in cash and a permanent chief executive and chair, while further board recruitment remains ongoing.
Management reported that early trading was ahead of internal expectations and has identified revenue growth, operating improvements and cash management as its priorities for the year.
The company’s financial performance will depend on trading across its existing businesses, operating expenditure and the execution of its stated plans.
Leave a Reply